Trial Profile
A Phase 2 Study to Assess the Effect of a Repeated Dose of XF-73 Nasal Gel on the Microbiological Burden of Commensal Staphylococcus Aureus Nasal Carriage in Surgical Patients at Risk of Post-operative Staphylococcal Infections
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Sep 2023
Price :
$35
*
At a glance
- Drugs Exeporfinium chloride (Primary)
- Indications Postoperative infections; Staphylococcal infections
- Focus Therapeutic Use
- Acronyms Landmark
- Sponsors Destiny Pharma
- 20 Sep 2023 According to a Destiny Pharma media release, data from this study were published in the leading US peer reviewed journal, Infection Control & Hospital Epidemiology
- 09 Jul 2021 According to a Destiny Pharma media release, data from this trial will be presented at 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
- 29 Mar 2021 Status changed from active, no longer recruiting to completed, according to a China Medical System Media Release.